Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Media / Science Center
  • Contact Us
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
    • Videos
  • Events & Presentations
    • Events
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
  • Videos
Aug 14, 2023 8:15am EDT

Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium

Aug 11, 2023 8:00am EDT

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

Aug 08, 2023 8:15am EDT

Ensysce Biosciences Announces IRB Approval of Key Study Protocol

Jul 26, 2023 8:05am EDT

Ensysce Biosciences Announces Engagement of Alacrita Consulting

Jun 27, 2023 8:05am EDT

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

Jun 13, 2023 4:15pm EDT

Ensysce Biosciences Regains Compliance with Nasdaq

Jun 07, 2023 9:55am EDT

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website

Jun 06, 2023 8:05am EDT

Ensysce Biosciences to Participate in Upcoming Industry Events

May 15, 2023 4:30pm EDT

Ensysce Biosciences Reports First Quarter 2023 Financial Results

May 12, 2023 4:40pm EDT

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio